ZyVersa Therapeutics (NASDAQ:ZVSA) Shares Up 20% – Still a Buy?

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA)’s stock price was up 20% during mid-day trading on Wednesday . The company traded as high as $0.24 and last traded at $0.24. Approximately 22,984 shares changed hands during trading, a decline of 82% from the average daily volume of 131,031 shares. The stock had previously closed at $0.20.

ZyVersa Therapeutics Price Performance

The company has a market cap of $1.90 million, a PE ratio of -0.18 and a beta of 0.81. The stock has a 50 day simple moving average of $0.16 and a two-hundred day simple moving average of $0.16.

About ZyVersa Therapeutics

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.